J&J makes $2B push in­to AD­Cs with Am­brx buy­out in on­col­o­gy deal spree: #JPM24

SAN FRAN­CIS­CO — John­son & John­son is adding to Big Phar­ma’s love for an­ti­body-drug con­ju­gates with a $2 bil­lion cash deal to swoop up Am­brx Bio­phar­ma …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.